XLO Earnings Xilio Therapeutics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated
Annual results
EPS
Revenue
Net income
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–24 of 24
| Q2 2026 | 2026-06-30 | -0.89 | 2026-08-12 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.58 | 2026-05-12 | 10-Q |
| FY 2025 | 2025-12-31 | -4.19 | 2026-03-23 | 10-K |
| Q3 2025 | 2025-09-30 | -0.43 | 2025-11-13 | 10-Q |
| Q2 2026 | 2025-06-30 | -4.76 | 2026-08-12 | 10-Q |
| Q1 2026 | 2025-03-31 | -2.49 | 2026-05-12 | 10-Q |
| FY 2025 | 2024-12-31 | -15.24 | 2026-03-23 | 10-K |
| Q3 2025 | 2024-09-30 | -0.91 | 2025-11-13 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.73 | 2025-08-14 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.62 | 2025-05-08 | 10-Q |
| FY 2024 | 2023-12-31 | -2.78 | 2025-03-11 | 10-K |
| Q3 2024 | 2023-09-30 | -2.14 | 2024-11-07 | 10-Q |
| Q2 2024 | 2023-06-30 | -1.53 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.83 | 2024-05-14 | 10-Q |
| FY 2023 | 2022-12-31 | -3.22 | 2024-04-01 | 10-K |
| Q3 2023 | 2022-09-30 | -2.40 | 2023-11-09 | 10-Q |
| Q2 2023 | 2022-06-30 | -1.68 | 2023-08-14 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.78 | 2023-05-09 | 10-Q |
| FY 2022 | 2021-12-31 | -13.52 | 2023-03-02 | 10-K |
| Q3 2022 | 2021-09-30 | -76.18 | 2022-11-09 | 10-Q |
| Q2 2022 | 2021-06-30 | -55.16 | 2022-08-09 | 10-Q |
| Q1 2022 | 2021-03-31 | -23.53 | 2022-05-12 | 10-Q |
| FY 2021 | 2020-12-31 | -105.42 | 2022-03-01 | 10-K |
| Q3 2021 | 2020-09-30 | -72.02 | 2021-12-02 | 10-Q |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.